Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. by Lopes, RD et al.
  	

Rationale and design of the Apixaban for the reduction of thrombo-embolism
in patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)
trial
Renato D. Lopes, Marco Alings, Stuart J. Connolly, Heather Beresh,
Christopher B. Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens C.
Nielsen, David Conen, Stefan H. Hohnloser, Georges H. Mairesse, Philippe
Mabo, A. John Camm, Jeffrey S. Healey
PII: S0002-8703(17)30127-8
DOI: doi: 10.1016/j.ahj.2017.04.008
Reference: YMHJ 5435
To appear in: American Heart Journal
Received date: 3 February 2017
Accepted date: 21 April 2017
Please cite this article as: Lopes Renato D., Alings Marco, Connolly Stuart J., Beresh
Heather, Granger Christopher B., Mazuecos Juan Benezet, Boriani Giuseppe, Nielsen
Jens C., Conen David, Hohnloser Stefan H., Mairesse Georges H., Mabo Philippe, Camm
A. John, Healey Jeﬀrey S., Rationale and design of the Apixaban for the reduction
of thrombo-embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation
(ARTESiA) trial, American Heart Journal (2017), doi: 10.1016/j.ahj.2017.04.008
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
Downloaded for Anonymous User (n/a) at McMaster University - Canada Consortium from ClinicalKey.com by Elsevier on May 25, 2017.
For personal use only. No other uses without permission. Copyright ©2017. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
 
Trial Design 
 
Rationale and design of the Apixaban for the Reduction of Thrombo-
Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation 
(ARTESiA) trial 
RCT# NCT01938248 
Renato D. Lopes, MD, MHS, PhD,
1
 Marco Alings, MD, PhD,
2
 Stuart J. Connolly, MD,
3
 Heather 
Beresh,
3
 Christopher B. Granger, MD,
1
 Juan Benezet Mazuecos, MD,
4
 Giuseppe Boriani, MD, 
PhD,
5
 Jens C. Nielsen, MD, DMSc,
6
 David Conen, MD, MPH,
3,7
 Stefan H. Hohnloser, MD,
8
 
Georges H. Mairesse, MD,
9
 Philippe Mabo, MD,
10
 A. John Camm, MD,
11
 and Jeffrey S. Healey, 
MD
3
 
 
1
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; 
2
Working 
Group on Cardiovascular Research, Utrecht, The Netherlands; 
3
Population Health Research 
Institute, Hamilton Health Sciences, McMaster University, Hamilton, Canada; 
4
Hospital 
Universitario Fundación Jimenez Díaz-Quironsalud, Madrid, Spain; 
5
Cardiology Division. 
Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and 
Reggio Emilia, Modena University Hospital, Modena, Italy; 
6
Aarhus University Hospital, 
Aarhus, Denmark; 
7 
Department of Medicine, University Hospital, Basel, Switzerland; 
8
Department of Cardiology, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany; 
9
Cliniques du Sud Luxembourg, Arlon, Belgium; 
10
Hôpital Pontchaillou, Rennes, France; 
11
St. 
George's University of London and Imperial College London, London, United Kingdom. 
 
Short title: ARTESiA Rationale and Design 
 
Address for correspondence: Renato D. Lopes, MD, MHS, PhD, Duke Clinical Research 
Institute, Box 3850, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705. E-mail: 
renato.lopes@duke.edu; Phone: 919-668-8241; Fax: 919-668-7056.  
  
Downloaded for Anonymous User (n/a) at McMaster University - Canada Consortium from ClinicalKey.com by Elsevier on May 25, 2017.
For personal use only. No other uses without permission. Copyright ©2017. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
ABSTRACT 
Background: Device-detected subclinical atrial fibrillation (AF) refers to infrequent, short-
lasting, asymptomatic AF that is detected only with long-term continuous monitoring. 
Subclinical AF is common and associated with an increased risk of stroke; however, the risk of 
stroke with subclinical AF is lower than for clinical AF, and very few patients with subclinical 
AF alone have been included in large AF anticoagulation trials. The net benefit of 
anticoagulation in patients with subclinical AF is unknown.  
Design: ARTESiA is a prospective, multicenter, double-blind, randomized controlled trial, 
recruiting patients with subclinical AF detected by an implanted pacemaker, defibrillator, or 
cardiac monitor, and who have additional risk factors for stroke. Patients with clinical AF 
documented by surface electrocardiogram will be excluded from the study. Participants will be 
randomized to receive either apixaban (according to standard AF dosing) or aspirin 81 mg daily. 
The primary outcome is the composite of stroke, transient ischemic attack with diffusion-
weighted magnetic resonance imaging evidence of cerebral infarction, and systemic embolism. 
Approximately 4000 patients will be enrolled from around 230 clinical sites, with an anticipated 
mean follow-up of 36 months until 248 adjudicated primary outcome events have occurred.  
Summary: ARTESi  will determine whether oral anticoagulation therapy with apixaban 
compared to aspirin reduces the risk of stroke or systemic embolism in patients with subclinical 
AF and additional risk factors.  
 
Key Words: apixaban, aspirin, atrial fibrillation, oral anticoagulation, stroke 
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Background 
Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide. The presence of AF 
increases the risk of stroke, and AF-related strokes are associated with higher mortality than 
strokes unrelated to AF. About one sixth of strokes are attributable to documented AF (1).  
Modern pacemakers and implantable cardioverter defibrillators (ICDs) can continuously 
monitor atrial rhythm. In patients with a pacemaker but without evidence for AF, device-detected 
atrial high-rate arrhythmias are common (2,3). These episodes, referred to as subclinical AF, are 
typically asymptomatic, of short duration (minutes to hours), and infrequent (4). Thus, 
subclinical AF differs from permanent, persistent, and paroxysmal AF diagnosed by various 
forms of surface electrocardiogram (ECG) monitoring. However, although subclinical AF is 
associated with stroke, the increase in risk appears to be somewhat lower than that with clinical 
AF (3,5). 
 
Subclinical AF and stroke risk 
Several studies have shown an association between the presence of subclinical AF and 
the risk of stroke. The summarized results of the trials that have investigated the risk of stroke 
associated with subclinical AF have recently been published (4). In the Mode Selection Trial in 
Sinus Node Dysfunction study, patients with sinus node dysfunction were randomized to dual 
chamber rate-modulated or single chamber ventricular pacing. In a subgroup analysis of this 
study, the presence of subclinical AF, defined as an atrial rate >220 bpm and lasting ≥5 minutes, 
was independently associated with death or non-fatal stroke (5). In the Prospective Study of the 
Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics 
(TRENDS) trial, patients with an indication for a pacemaker or an ICD and an additional risk 
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factor for stroke were included (2). Subclinical AF was defined as an episode of a rapid atrial 
rate >170 bpm, lasting ≥20 seconds. At the end of a mean follow-up of 1.4 years, at least one 
episode of subclinical AF was observed in 47% of patients. In this study, the presence of 
subclinical AF was associated with thromboembolic risk, and this risk was related to the burden 
of subclinical AF. Subclinical AF duration of >5.5 hours/day (the median value in the study) 
doubled the risk for thromboembolic events to 2.4%/year, while no increase in stroke risk was 
observed in patients with a lower burden of subclinical AF (2).  
The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and 
the Atrial Fibrillation Reduction Atrial Pacing (ASSERT) study included patients 65 years and 
older with a history of hypertension, a recent pacemaker or ICD implant, and no history of AF. 
Subclinical AF was defined as an episode of a rapid atrial rate >190 bpm, lasting >6 minutes. 
Within 3 months after implantation, subclinical AF was detected in 10% of the patients. During a 
mean follow-up of 2.5 years, subclinical AF was detected in 35% of the patients. The presence of 
subclinical AF during the first 3 months after pacemaker implantation was associated with a 
fivefold increase in the risk of developing clinical AF, and a 2.5-fold increase in the risk for 
ischemic stroke or systemic embolism (3). 
Although subclinical AF is associated with stroke, this risk appears to be low compared 
to the stroke risk in patients with similar risk profiles and clinical AF. In TRENDS, the mean 
CHADS2 score was 2.2, and the stroke rate in patients with episodes of subclinical AF was 
2.4%/year (2). In ASSERT, the mean CHADS2 score was 2.2 and 2.3 in patients with and 
without subclinical AF, respectively. In patients with a baseline CHADS2 score >2 and 
subclinical AF detected between enrollment and 3 months, the annual stroke rate was 3.78% (3). 
Although this represents an almost fourfold increase compared to the annual stroke risk of 
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patients without subclinical AF during the first 3 months after pacemaker implantation, this is 
substantially lower than the >5.9% annual stroke risk of patients with clinical AF and a CHADS2 
score >2 (6). Thus, after adjustment for risk factors for stroke, subclinical AF may be associated 
with a lower absolute stroke risk compared with clinical AF. 
 
Anticoagulation therapy for stroke prevention in AF and subclinical AF 
The overall efficacy of anticoagulation therapy for stroke prevention in AF has been well 
established (7). More recently, the efficacy and safety of non-vitamin K antagonist oral 
anticoagulants (NOACs) for stroke prevention have been established in pivotal phase 3 trials 
with thousands of patients (8-11). Overall, when compared with warfarin, NOACs significantly 
reduced the risk of stroke, intracranial hemorrhage, and mortality, with similar risk for major 
bleeding but increased risk of gastrointestinal bleeding (12). However, there were very few 
subclinical AF patients enrolled in any of these large trials. Patients with pacemakers especially 
tend to be extremely elderly and may have a high bleeding risk from anticoagulation. Thus, it is 
unknown whether there is a positive risk/benefit ratio for oral anticoagulation in patients with 
subclinical AF, and this question can only be conclusively answered by means of a randomized 
clinical trial. The rationale for such a trial is further supported by the observation that with 
prolonged monitoring via an implanted device, subclinical AF is frequently observed. For 
example, in ASSERT, the cumulative incidence of a subclinical AF episode of greater than 6 
minutes by 3.5 years was almost 50%. Increasingly, physicians are using implanted devices such 
as the Medtronic Reveal recorder to detect arrhythmias in patients and even in those without 
symptoms. It is also likely that in the near future, detection of subclinical AF-like episodes will 
be possible by means of wearable devices such as smart watches. The increasingly common 
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detection of subclinical AF and subclinical AF-like episodes will require better understanding of 
the role of anticoagulation in subclinical AF. 
Given the uncertainty of the risk/benefit ratio of oral anticoagulation for stroke 
prevention in patients with device-detected subclinical AF, specific recommendations in most 
guidelines for AF management are scarce and rarely similar. The 2014 Canadian Cardiovascular 
Society Guidelines recommend oral anticoagulation therapy for patients with subclinical AF who 
are ≥65 years of age, with a CHADS2 score ≥ 1 and episodes that last more than 24 hours, or for 
shorter episodes only if the patient is high risk, such as having a history of recent cryptogenic 
stroke (13). The 2016 European Society of Cardiology Guidelines, on the other hand, indicate 
that it is unclear whether subclinical AF implies the same therapeutic requirements as clinically 
overt AF, and recommend that patients with subclinical AF should undergo further ECG 
monitoring to document AF before initiating AF therapy (14). Few patients with subclinical AF 
were enrolled in the trials that studied anticoagulation in patients with AF. Thus, the question of 
whether this therapeutic approach is beneficial for patients with subclinical AF remained to be 
investigated in a large randomized trial. A four-country survey in Canada and Europe showed a 
heterogeneity in the opinions of cardiologists involved in the care of patients with pacemakers 
toward the role of anticoagulation therapy in patients with subclinical AF (15). Importantly, most 
of them were willing to enroll patients in a randomized trial.  
The Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-
Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial was designed to determine whether 
treatment with apixaban compared to aspirin reduces the risk of stroke or systemic embolism in 
patients with subclinical AF and additional risk factors for stroke. The favorable risk/benefit ratio 
of apixaban shown in previous AF studies (Apixaban for Reduction in Stroke and Other 
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Thromboembolic Events in Atrial Fibrillation [ARISTOTLE] and Apixaban Versus 
Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are 
Unsuitable for Vitamin K Antagonist Treatment [AVERROES]) (8,16) supports the hypothesis 
that prophylactic apixaban will have a net beneficial effect in patients with subclinical AF. 
 
Methods 
Study overview 
ARTESiA (ClinicalTrials.gov # NCT01938248) is a prospective, multicenter, double-
blind, randomized controlled trial that will recruit patients with subclinical AF detected by either 
a pacemaker, ICD, or insertable cardiac monitor, and who also have other risk factors for stroke 
and no requirement for anticoagulation therapy. Eligible, consenting patients will be enrolled and 
randomized to receive aspirin or apixaban. The study will be conducted at approximately 230 
sites in the United States, Canada, and Europe.  
This trial will be conducted in compliance with the study protocol, principles laid down 
in the Declaration of Helsinki, and Good Clinical Practice guidelines as defined by the 
International Conference on Harmonization where applicable. Prior to patient participation, 
written informed consent will be obtained from each patient or the patient’s legally accepted 
representative, and will comply with the Declaration of Helsinki and applicable local regulations. 
 
Study population  
The ARTESiA trial will include approximately 4000 participants. Key inclusion and 
exclusion criteria are shown in Table I. Device interrogation output (i.e., an episode log) 
documenting at least one episode of subclinical AF ≥ 6 minutes in duration will be required as 
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evidence of eligibility. The subclinical AF episode may have occurred at any time in the past. If 
the episode lasted < 6 hours, electrogram documentation will also be collected for central 
verification. Episodes of subclinical AF ≥ 6 hours will not require electrogram documentation 
because previous studies have shown that there is a very high correlation between such reports 
and true subclinical AF (17). For these longer episodes, device logs will be considered sufficient 
documentation to confirm eligibility. Patients with any single episode of subclinical AF > 24 
hours in duration at any time prior to enrollment will not be included. 
In addition to having subclinical AF, eligible patients must satisfy the following study 
criteria for stroke risk: A) previous stroke, or transient ischemic attack, or systemic embolism, or 
age 75 years or greater; B) age 65-74 and two additional risk factors; or C) age 55-64 and three 
additional risk factors (Figure 1). The risk factors for stroke are female sex, hypertension, heart 
failure, diabetes, and vascular disease (coronary artery disease, peripheral artery disease, or 
aortic plaque) (Table II).  
 
Randomization, treatment, and follow-up 
Enrolled patients will be randomized (interactive web-based) in a 1:1 ratio between 
aspirin and apixaban (Figure 2). Double-blind treatment will be achieved using a double-dummy 
technique. Each patient will take three study pills per day: a single aspirin or placebo aspirin and 
two doses of apixaban or placebo apixaban. Apixaban dosage will be 5 mg twice daily (or 2.5 
mg twice daily for patients having 2 or more of the following characteristics: age ≥ 80 years, 
weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL). During the course of the trial, apixaban 
dosage will be down-titrated if patients develop 2 or more of these dose reduction criteria. Those 
assigned to aspirin will receive a dose of 81 mg once daily.  
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Follow-up will occur at 30 days after enrollment, at 6 months after enrollment, and every 
6 months thereafter until the end of the study, with an anticipated mean follow-up of 
approximately 36 months. As this is an event-driven study, the precise termination of follow-up 
will occur once 248 adjudicated primary efficacy outcome events have occurred.  
 
Study outcomes 
The primary efficacy outcome is a composite of stroke and systemic embolism. Stroke 
will be defined as the rapid onset of a new persistent neurologic deficit attributed to an 
obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular 
cause (e.g., trauma, tumor, or infection). Signs or symptoms must last at least 24 hours, unless 
supported by clear evidence of cerebral infarction on diffusion-weighted magnetic resonance 
imaging. Available neuroimaging studies will be considered to support the clinical impression 
and to determine whether there is a demonstrable lesion compatible with an acute stroke. Strokes 
will be classified as ischemic, hemorrhagic, or unknown. Stroke includes transient ischemic 
attack with corresponding evidence of cerebral infarction on diffusion-weighted magnetic 
resonance imaging (18). Stroke disability will be classified using the modified Rankin Scale at 
day 7 or at hospital discharge (whichever comes first), and again at the next scheduled follow-up 
visit following the event. 
A systemic arterial embolism will be considered to have occurred where there is clear 
evidence of abrupt occlusion of a systemic artery consistent with an embolic event. It will not 
include arterial occlusions that are not embolic, nor will it include pulmonary embolism. In 
addition to clinical signs and symptoms consistent with embolic arterial occlusion, there should 
be at least one of the following objective findings of arterial embolism: surgical report indicating 
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evidence of arterial embolism, pathological specimens related to embolism removal, imaging 
evidence consistent with arterial embolism, or autopsy reports. 
The main safety outcome will be the occurrence of clinically overt major bleeding as 
defined by the International Society of Thrombosis and Haemostasis criteria: fatal bleeding; 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, 
retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; or 
bleeding causing an acute fall in hemoglobin level of ≥2 g/dL or leading to transfusion of two or 
more units of whole blood or red cells (19). 
Secondary outcomes will include ischemic stroke, myocardial infarction, vascular death, 
total death (vascular and non-vascular), the composite of stroke, myocardial infarction, systemic 
embolism and total death, and the composite of stroke, myocardial infarction, systemic 
embolism, total death, and major bleeding. All primary events and major bleeding will be 
adjudicated. 
Device interrogation data will be collected throughout study follow-up to allow for a 
better understanding of AF burden and subclinical AF frequency and duration in this population. 
In addition, the following cardiovascular outcomes that are common in this patient population 
will be assessed: clinical AF (detected by surface ECG), hospitalization for heart failure, 
cardioversion, and ablation for AF. 
 
Sample size calculation and statistical analysis 
Among ASSERT patients with risk factors similar to patients who will be enrolled in 
ARTESiA, the annual rate of stroke and systemic embolism was 2.75%. Assuming an event rate 
of 2.75% per year in the proposed population with an anticipated mean follow-up period of 3 
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years and using a two-sided significance level of 0.05, a sample size of 3719 is required to 
provide 80% power to detect a 35% relative risk reduction, allowing for a combined dropout and 
crossover rate of 8.5% over the course of the study. The study will enroll approximately 4000 
participants. A total of 248 primary outcome events will be required.  
The analysis of the main trial results will be performed following the intention-to-treat 
principle (i.e., all patients randomized in the study will be included in the analysis). Patients will 
be included in their assigned treatment groups regardless of the actual treatment they received. 
An on-treatment analysis will include all treated subjects (randomized subjects who received at 
least one dose of the assigned study drug). In this analysis, subjects will be categorized to the 
treatment group to which they were assigned unless they received the incorrect treatment. 
Subjects who received the incorrect treatment will be excluded from this analysis population. 
Follow-up will be censored at 6 days after discontinuation of study medication.  
The rates of the primary efficacy outcome (stroke or systemic embolism) and primary 
safety outcome (major bleeding) will be presented for the two treatment groups using the 
Kaplan-Meier method, and comparisons between the groups will be performed using a log-rank 
test. Adjusted and unadjusted treatment effects as measured by the hazard ratio with two-sided 
95% confidence interval will be derived by the Cox proportional hazards model. Six subgroup 
analyses of the main trial study outcome are prespecified to compare (1) patients whose longest 
baseline episode of subclinical AF is longer vs. shorter than the median value for the study 
population, (2) patients with different CHA2DS2-VASc scores, (3) patients <75 and ≥75 years of 
age, (4) patients with and without a prior history of stroke or transient ischemic attack, (5) 
patients with a chronic pacemaker/ICD/cardiac resynchronization therapy (≥ 2 years) vs. newly 
implanted pacemaker/ICD/cardiac resynchronization therapy (< 2 years) vs. insertable cardiac 
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monitor, and (6) patients with ICD vs pacemaker vs insertable cardiac monitor. Homogeneity of 
treatment effect in subgroups, both in magnitude and direction, will be assessed by adding a 
covariate for the subgroup variable and the corresponding treatment-subgroup interaction to the 
respective non-stratified Cox proportional hazards model used in the main analysis. Significant 
interactions in the analysis of the primary outcome will be interpreted as “flags” to prompt 
further investigation. Following the test of interaction, treatment effect will be estimated 
separately within each level of a subgroup variable using a stratified Cox proportional hazards 
model. 
 
Steering and Data Monitoring Committees 
The ARTESiA Steering Committee comprises the national leads from each participating 
country and oversees the design, execution, analysis, and reporting of the study, and will assign 
appropriate responsibilities to the other committees. The Steering Committee holds the primary 
responsibility for publication of the study results. This committee will convene regularly by 
teleconference for meetings to address policy issues and monitor study progress, execution, and 
management.  
An independent Data Monitoring Committee, composed of one neurologist, two 
cardiologists, one thrombosis expert, and one statistician, will review serious adverse events, 
adverse drug effects, and primary outcome data on a 6-month basis and reports to the Steering 
Committee. Two formal interim analyses will be done after 82 and 164 primary outcome events 
have occurred.  
The Data Monitoring Committee may in exceptional circumstances recommend 
termination of the study for a safety concern that is assessed to outweigh potential benefits. No 
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formal boundaries will be used for terminating the study for safety reasons, but clear and 
consistent evidence of net harm that overrides any benefit should be apparent. In the case that 
risk outweighs benefit in these two important outcomes, the committee may recommend that the 
study be stopped early for “harm.”  
The modified Haybittle-Peto rule will be used to guide the decision regarding early 
stopping: a reduction of 4 standard deviations (α = 0.00006) in the analysis of the primary 
outcome at the first interim analysis or 3 standard deviations (α = 0.0027) at the second interim 
analysis. If the monitoring boundary is crossed at either of the 2 interim analyses, a second look 
will be conducted after at least 3-6 months to confirm the boundary remains crossed and that 
the trend in treatment effect is not temporary. The α-level for the final analysis will remain the 
conventional 0.05 given the paucity of interim analyses, their extremely low α-levels, and the 
requirement for confirmation with subsequent analyses. 
 
Support 
ARTESiA is an investigator-initiated study, supported by grants from the Canadian 
Institutes for Health Research, Canadian Stroke Prevention Intervention Network, the Bristol-
Myers Squibb and Pfizer Alliance, Hamilton Health Sciences Foundation, and Medtronic, Inc. 
The authors are solely responsible for the design and conduct of this study, all study analyses, the 
drafting and editing of the paper and its final contents. 
 
Discussion 
Subclinical AF is characterized by relatively short episodes of atrial high-rate 
arrhythmias that are detected only with continuous monitoring and are mostly asymptomatic. 
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Subclinical AF differs from clinically overt AF, which occurs more often, with symptoms, and is 
documented on ECG. Several studies have shown an association between the presence of 
subclinical AF and the risk of stroke (2–5).  
However, there is debate on the minimum duration of subclinical AF that is required to 
confer this stroke risk. For eligibility in the ARTESiA trial, subclinical AF episode duration 
between 6 minutes and 24 hours was chosen based primarily on the ASSERT study, since it was 
observed that episodes of subclinical AF lasting at least 6 minutes were associated with an 
increased risk of stroke, and when episodes of subclinical AF were longer than 24 hours, this risk 
was much higher. A recent publication of the Canadian Cardiovascular Society recommended 
oral anticoagulation therapy for patients with subclinical AF lasting >24 hours when the patient 
is aged ≥ 65 years or with CHADS2 score ≥ 1, or for shorter episodes if the patient is considered 
to be at high risk (13). The 2016 European Society of Cardiology Guidelines limit the 
consideration of oral anticoagulants in patients with subclinical AF, except for special 
circumstances (14). 
A recent review on stroke prevention in patients with subclinical AF suggests 
anticoagulating patients with subclinical AF if a history of ischemic stroke is present (20). 
Observations from the ASSERT II trial, however, may challenge the importance of history of 
ischemic stroke in this setting. Using an implantable loop recorder, the ASSERT II trial studied 
the prevalence of subclinical AF among older individuals without pacemakers. With an annual 
incidence of 34.4%, subclinical AF episodes ≥5 minutes were common in asymptomatic elderly 
patients. Patients with prior stroke were not more likely to have subclinical AF than patients 
without prior stroke (21). The current need for scientific evidence investigating stroke prevention 
in device-detected subclinical AF has been highlighted (22). 
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Whether subclinical AF is the same direct risk factor for stroke as clinical AF or is only a 
risk marker with a different mechanism is unclear. Therefore, patients with subclinical AF may 
respond differently to anticoagulants than patients with clinical AF. Results from TRENDS, the 
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce 
Stroke Risk (IMPACT) study, and a time-dependent analysis for ASSERT all indicate that there 
is no clear temporal association between episodes of subclinical AF and stroke (2,23,24). The 
absence of a temporal relationship between subclinical AF and the occurrence of stroke 
challenges the conventional understanding of a mechanistic relationship between atrial stasis, 
clot formation, and embolism. Stroke in patients with subclinical AF may be delayed or may be 
caused by a different factor. IMPACT was the first trial of anticoagulation in device-detected 
subclinical AF but used a complex treatment strategy, stopping treatment if no further subclinical 
AF episodes were seen in a period of time (24). Early initiation of anticoagulation based on 
device-detected subclinical AF did not improve outcomes, in part because of temporal 
dissociation between AF and stroke, and possibly because of stroke mechanisms independent of 
subclinical AF (25). In this trial, a possible explanation for the lack of observed benefit of the 
monitoring strategy is that the idea that stroke risk increases for a defined period after subclinical 
AF may be incorrect. Previous data have suggested that in the majority of cases of subclinical 
AF-associated stroke, no AF occurred within 1-3 months of the stroke. Another important issue 
was the use of a composite primary outcome including stroke and major bleeding. The 
components of this composite outcome may have offset each other, which could have contributed 
to a neutral result (25). In clinical practice, the relationship between subclinical AF and stroke is 
likely complex, and different for different patients: in some, a temporally linked, causal 
relationship, while in others, simply a marker of stroke risk. Therefore, the results of the 
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IMPACT trial do not support urgent initiation or any later withdrawal of anticoagulation in 
response to incident subclinical AF or its termination, and argue instead for anticoagulation 
based on more comprehensive, individualized assessment of risk and benefit. Additional studies 
like ARTESiA will help elucidate stroke mechanisms in patients with advanced heart disease to 
inform anticoagulation decision making for AF detected by implanted cardiac rhythm 
management devices. 
Apixaban is a factor Xa inhibitor that has been shown to be effective in a variety of 
conditions where oral anticoagulation can be used, including the reduction of venous 
thromboembolism and stroke. In the AVERROES and ARISTOTLE trials, apixaban was 
effective and safe for patients with non-valvular AF compared with aspirin or dose-adjusted 
warfarin (8,16). The Apixaban after the Initial Management of Pulmonary Embolism and Deep 
Vein Thrombosis with First-Line Therapy–Extended Treatment (AMPLIFY-EXT) study showed 
that extended use of apixaban was safe, with similar rates of major bleeds when compared to 
placebo (26). Thus, the consistently favorable risk/benefit ratio of apixaban led to the selection of 
apixaban in the design of ARTESiA. 
Aspirin was chosen as the control for the ARTESiA study because it is a common 
medication for secondary prevention in this population of patients with multiple risk factors, and 
modestly reduces the risk of ischemic stroke. Instead of combining the use of apixaban and 
aspirin, which would likely increase the risk of bleeding events in these patients, we have chosen 
to compare apixaban with aspirin. Our study, however, will allow the use of open label aspirin 
up to 100 mg/day in addition to study medication in situations where the treating physician 
considers aspirin to be appropriate.  
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Finally, patients who develop symptomatic clinical AF documented by surface ECG 
during the study period should be taken off the study drug and switched to non-study 
anticoagulant therapy as recommended by current guidelines. If a clinical indication for 
anticoagulation or dual antiplatelet therapy arises, the study drug will be discontinued or 
interrupted. If patients develop subclinical AF with episode duration > 24 hours, the decision to 
discontinue blinded study drug and start non-study anticoagulant therapy will be left to the 
discretion of the investigator. Participants will continue with follow-up and may restart study 
medications if and when the clinical indication for these other therapies resolves. Unblinding of 
study medication will be avoided unless knowledge of the treatment allocation is required to 
make an urgent treatment decision. 
 
Conclusions 
The ARTESiA trial will compare apixaban with aspirin to reduce the risk of stroke in 
patients with subclinical AF and additional risk factors for stroke. The study findings will 
generate evidence to address this gap in scientific knowledge and will help inform 
antithrombotic strategies for these patients.  
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Figure 1. Eligibility criteria for the ARTESiA trial. AF, atrial fibrillation; CAD, coronary artery 
disease; DM, diabetes; HF, heart failure; HTN, hypertension; PAD, peripheral artery disease; SE, 
systemic embolism; TIA, transient ischemic attack. 
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Figure 2. ARTESiA trial design. AF, atrial fibrillation; bid, twice daily; ISTH, International 
Society of Thrombosis and Haemostasis; OAC, oral anticoagulant; OD, once daily; TIA, 
transient ischemic attack. *A 2.5-mg dose of apixaban will be given twice daily for subjects who 
have 2 or more of the following characteristics: age ≥ 80 years, weight ≤ 60 kg, or serum 
creatinine ≥ 1.5 mg/dL. 
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Table I. Key inclusion and exclusion criteria. 
Inclusion Criteria 1. Permanent pacemaker or defibrillator with atrial lead (with or without 
resynchronization) or a single-chamber device with an AF detection 
algorithm similar to those employed in implantable loop recorders, or 
insertable cardiac monitor capable of detecting SCAF 
2. At least one episode of device-detected SCAF ≥ 6 minutes in duration 
(atrial rate > 175/min if an atrial lead is present), but no single episode > 24 
hours in duration at any time prior to enrollment. SCAF requires at least 
one episode of electrogram confirmation (unless ≥ 6 hours in duration) 
3. Age ≥ 55 years  
4. Risk factors for stroke (any of the following):  
 Previous stroke, TIA, or SE 
 ≥ 75 years old 
 65-74 years old + at least 2 risk factors* 
 55-64 years old + at least 3 risk factors* 
*Risk factors: female gender, hypertension, heart failure, diabetes, vascular 
disease (coronary artery disease, peripheral artery disease, or aortic plaque) 
Exclusion Criteria 1. Clinical atrial fibrillation documented by surface ECG (12 lead ECG, 
Telemetry, Holter) lasting ≥ 6 minutes, with or without clinical symptoms 
2. Mechanical valve prosthesis, recent (within past 6 months) deep vein 
thrombosis or pulmonary embolism or other condition requiring treatment 
with an anticoagulant 
3. Allergy to aspirin or apixaban 
4. Severe renal insufficiency (serum creatinine > 2.5 mg/dL [221 µmol/L] or a 
calculated creatinine clearance < 25 ml/min) 
5. Serious bleeding in the last 6 months or at high risk of bleeding (this 
includes, but is not limited to: prior intracranial hemorrhage, active peptic 
ulcer disease, clinically significant thrombocytopenia or anemia, recent 
stroke within past 10 days, documented hemorrhagic tendencies or blood 
dyscrasias) 
6. Moderate to severe hepatic impairment 
7. Ongoing need for combination therapy with aspirin and clopidogrel (or 
other combination of two platelet inhibitors) 
8. Meets criteria for requiring lower dose of apixaban AND also has ongoing 
need for strong inhibitors of both CYP3A4 and P-glycoprotein (e.g., 
ketoconazole, itraconazole, ritonavir or clarithromycin) 
9. Ongoing need for strong dual inducers of both CYP3A4 and P-glycoprotein 
(e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) 
10. Received an investigational drug in the past 30 days 
11. Participants considered by the investigator to be unsuitable for the study for 
any of the following reasons: 
 Not agreeable for treatment with either aspirin or apixaban or 
anticipated to have poor compliance on study drug treatment 
 Unwilling to attend study follow-up visits  
 Life expectancy less than 2 years due to concomitant disease 
12. Women who are pregnant, breast-feeding or of child-bearing potential 
without an acceptable form of contraception in place (sterilization, 
abstinence or other method with less than 1% failure rate) 
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Table II. Guidance for stroke risk factors.  
Risk Factor Guidance 
Stoke or TIA Any clinical history of stroke (signs or 
symptoms ≥ 24 hours) or TIA (signs or 
symptoms < 24 hours) OR CT or MRI 
evidence of prior silent infarction (with or 
without symptoms). 
Systemic arterial embolism Any clinical history of systemic arterial 
embolism. 
Hypertension Any history of hypertension requiring 
antihypertensive treatment OR 2 blood 
pressure readings > 140/90 (either value) on 
separate days taken after 5 minutes rest and 
which would, in the opinion of the treating 
physician, require treatment with 
antihypertensive therapy. 
Heart failure Clinical heart failure diagnosed at any time 
OR a left ventricular ejection fraction < 50%/ 
Diabetes Known history of diabetes OR currently 
taking insulin or any oral diabetic medication 
OR HbA1c > 8% OR fasting blood sugar > 14 
mmol/L.  
Vascular disease Evidence of atherosclerosis on coronary 
angiogram, nuclear testing, or stress testing, 
or evidence of aortic or peripheral arterial 
disease using ultrasound, CT, or MRI 
imaging. Vascular disease need only be 
present, not necessarily flow-limiting or 
symptomatic. 
CT = computed tomography; HbA1c = glycated hemoglobin; MRI = magnetic resonance 
imaging; TIA = transient ischemic attack. 
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